Abstract 155 Tb [t 1/2= 5.32 d, E γ= 87 keV (32%); 105 keV (25%)(IAEA, 2021) is a novel
promising radionuclide for theranostic applications in nuclear medicine. Its physical …

The availability of novel radionuclides plays a fundamental role in the development of
personalized nuclear medicine. In particular, there is growing interest in pairs formed by two …

Radiometals play a fundamental role in the development of personalized nuclear medicine.
In particular, copper radioisotopes are attracting increasing interest since they offer a varying …

The availability of novel medical radionuclides is a key point in the development of
personalised nuclear medicine. In particular, copper radioisotopes are attracting …

The future development of personalized nuclear medicine relies on the availability of novel
medical radionuclides. In particular, radiometals are attracting considerable interest since …

The characterization of particle accelerator induced neutron fields is challenging but
fundamental for research and industrial activities, including radiation protection, neutron …

Abstract 44 Sc is a β+-emitter which has been extensively studied for nuclear medicine
applications. Its promising decay characteristics [t 1/2= 3.97 h, E β+= 632 keV (94.3%), E γ …

Abstract 165 Er is a pure Auger-electron emitter with promising characteristics for
therapeutic applications in nuclear medicine. The short penetration path and high Linear …

The concept of theranostics in nuclear medicine is based on the use of a pair of
radioisotopes to label radiopharmaceuticals for both diagnosis and therapy and is essential …

Introduction: Targeted Radionuclide Therapy is used for the treatment of tumors in nuclear
medicine, while sparing healthy tissues. Its application to cancer treatment is expanding. In …